Sandra M. S. Monteiro

Sandra M. S. Monteiro

Auto-generated profile, based on publicly available information

Sandra M. S. Monteiro

BET, Instituto de Biologia Experimental e Tecnológica, (Institute of Experimental and Technological Biology), Oeiras, Portugal

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2008 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
SMSandra M. Monteiro
Sandra M. Monteiro
JCJoão J. Clemente
João J. Clemente
AHAdriano O. Henriques
Adriano O. Henriques
RGRui J. Gomes
Rui J. Gomes
MOManuel D. Ortigueira
Manuel D. Ortigueira
ACAntónio E. Cunha
António E. Cunha
Bacillus subtilis spores have a number of potential applications, which include their use as probiotics and competitive exclusion agents to control zoonotic pathogens in animal production. The effect of cultivation conditions on Bacillus subtilis growth and sporulation was investigated in batch bioreactions performed at a 2-L scale. Studies of the cultivation conditions (pH, dissolved oxygen concentration, and media composition) led to an increase of the maximum concentration of vegetative cell from 2.6 x 10(9) to 2.2 x 10(10) cells mL(-)(1) and the spore concentration from 4.2 x 10(8) to 5.6 x 10(9) spores mL(-)(1). A fed-batch bioprocess was developed with the addition of a nutrient feeding solution using an exponential feeding profile obtained from the mass balance equations. Using the developed feeding profile, starting at the middle of the exponential growth phase and finishing in the late exponential phase, an increase of the maximum vegetative cell concentration and spore concentration up to 3.6 x 10(10) cells mL(-)(1) and 7.4 x 10(9) spores mL(-)(1), respectively, was obtained. Using the developed fed-batch bioreaction a 14-fold increase in the concentration of the vegetative cells was achieved. Moreover, the efficiency of sporulation under fed-batch bioreaction was 21%, which permitted a 19-fold increase in the final spore concentration, to a final value of 7.4 x 10(9) spores mL(-)(1). This represents a 3-fold increase relative to the highest reported value for Bacillus subtilis spore production.

24 February 2021 in Biotechnology and Bioengineering
Verified
Journal Article
Open access
PDF file
RCRute Castro
Rute Castro
Ligia SaraivaLigia Saraiva
Ligia Saraiva
RERute P. Eleutério
Rute P. Eleutério
MTMónica Thomaz
Mónica Thomaz
APAntónio Pires
António Pires
PAPaula M Alves
Paula M Alves
Serological assays are valuable tools to study SARS‐CoV‐2 spread and, importantly, to identify individuals that were already infected and would be potentially immune to a virus reinfection. SARS‐CoV‐2 Spike protein and its receptor binding domain (RBD) are the antigens with higher potential to develop SARS‐CoV‐2 serological assays. Moreover, structural studies of these antigens are key to understand the molecular basis for Spike interaction with angiotensin converting enzyme 2 receptor, hopefully enabling the development of COVID‐19 therapeutics. Thus, it is urgent that significant amounts of this protein became available at the highest quality. In this study, we produced Spike and RBD in two human derived cell hosts: HEK293‐E6 and Expi293F™. We evaluated the impact of different and scalable bioprocessing approaches on Spike and RBD production yields and, more importantly, on these antigens' quality attributes. Using negative and positive sera collected from human donors, we show an excellent performance of the produced antigens, assessed in serologic enzyme‐linked immunosorbent assay (ELISA) tests, as denoted by the high specificity and sensitivity of the test. We show robust Spike productions with final yields of approx. 2 mg/L of culture that were maintained independently of the production scale or cell culture strategy. To the best of our knowledge, the final yield of 90 mg/L of culture obtained for RBD production, was the highest reported to date. An in‐depth characterization of SARS‐CoV‐2 Spike and RBD proteins was performed, namely the antigen's oligomeric state, glycosylation profiles, and thermal stability during storage. The correlation of these quality attributes with ELISA performance show equivalent reactivity to SARS‐CoV‐2 positive serum, for all Spike and RBD produced, and for all storage conditions tested. Overall, we provide straightforward protocols to produce high‐quality SARS‐CoV‐2 Spike and RBD antigens, that can be easily adapted to both academic and industrial settings; and integrate, for the first time, studies on the impact of bioprocess with an in‐depth characterization of these proteins, correlating antigen's glycosylation and biophysical attributes to performance of COVID‐19 serologic tests.

1 June 2005 in Cytotechnology
Verified
Journal Article
Closed access
PDF file
KKKarl Kreij
Karl Kreij
CMCarl-Fredrik Mandenius
Carl-Fredrik Mandenius
JCJoão J. Clemente
João J. Clemente
ACAntónio Eduardo Cunha
António Eduardo Cunha
SMSandra M. S. Monteiro
Sandra M. S. Monteiro
JMJan Mitrovics
Jan Mitrovics

1 September 2021 in New Biotechnology
Verified
Journal Article
Closed access
JSJoana Sales-Dias
Joana Sales-Dias
AFAndreia Ferreira
Andreia Ferreira
MLMárcia Lamy
Márcia Lamy
Giacomo DomeniciGiacomo Domenici
Giacomo Domenici
SMSandra M.S. Monteiro
Sandra M.S. Monteiro
ABAna Barbas
Ana Barbas

3 April 2008 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
JCJ.J. Clemente
J.J. Clemente
SMS.M.S. Monteiro
S.M.S. Monteiro
MOManuel D. Ortigueira
Manuel D. Ortigueira
ACA.E. Cunha
A.E. Cunha